76 related articles for article (PubMed ID: 19730355)
1. A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.
Im CK; Rha SY; Jeung HC; Ahn JB; Shin SJ; Noh SH; Roh JK; Chung HC
Am J Clin Oncol; 2010 Feb; 33(1):56-60. PubMed ID: 19730355
[TBL] [Abstract][Full Text] [Related]
2. Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
Sakamoto T; Yasui H; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Machida N; Todaka A; Tomita H; Tsushima T; Taniguchi H; Hamauchi S
Int J Clin Oncol; 2010 Jun; 15(3):287-93. PubMed ID: 20217447
[TBL] [Abstract][Full Text] [Related]
3. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
Higuchi K; Tanabe S; Shimada K; Hosaka H; Sasaki E; Nakayama N; Takeda Y; Moriwaki T; Amagai K; Sekikawa T; Sakuyama T; Kanda T; Sasaki T; Azuma M; Takahashi F; Takeuchi M; Koizumi W;
Eur J Cancer; 2014 May; 50(8):1437-45. PubMed ID: 24560487
[TBL] [Abstract][Full Text] [Related]
4. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.
Bouché O; Raoul JL; Bonnetain F; Giovannini M; Etienne PL; Lledo G; Arsène D; Paitel JF; Guérin-Meyer V; Mitry E; Buecher B; Kaminsky MC; Seitz JF; Rougier P; Bedenne L; Milan C;
J Clin Oncol; 2004 Nov; 22(21):4319-28. PubMed ID: 15514373
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Baba E; Esaki T; Ariyama H; Mitsugi K; Morikita T; Fujishima H; Kusaba H; Nakano S; Akashi K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):611-7. PubMed ID: 21116623
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
7. Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.
Baek JH; Kim JG; Sohn SK; Kim DH; Lee KB; Song HS; Kwon KY; Do YR; Ryoo HM; Bae SH; Park KU; Kim MK; Lee KH; Hyun MS; Chung HY; Yu W
J Korean Med Sci; 2005 Dec; 20(6):966-70. PubMed ID: 16361806
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer.
Shen WC; Yang TS; Hsu HC; Chen JS
Chang Gung Med J; 2011; 34(6):590-8. PubMed ID: 22196061
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
Ueda S; Hironaka S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
Gastric Cancer; 2006; 9(3):203-7. PubMed ID: 16952039
[TBL] [Abstract][Full Text] [Related]
13. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
Cho EK; Lee WK; Im SA; Lee SN; Park SH; Bang SM; Park DK; Park YH; Shin DB; Lee JH
Oncology; 2005; 68(4-6):333-40. PubMed ID: 16020960
[TBL] [Abstract][Full Text] [Related]
15. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Rosati G; Cordio S; Caputo G; Condorelli S; Germano D; Mattina M; Amadio P; Reggiardo G; Manzione L
J Chemother; 2007 Oct; 19(5):570-6. PubMed ID: 18073157
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Yilmaz U; Oztop I; Alacacioglu A; Yaren A; Tarhan O; Somali I
Chemotherapy; 2006; 52(5):264-70. PubMed ID: 16873996
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer.
Jeung HC; Rha SY; Noh SH; Roh JK; Chung HC
Cancer Chemother Pharmacol; 2007 Feb; 59(3):313-20. PubMed ID: 16770582
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.
Boku N; Ohtsu A; Shimada Y; Shirao K; Seki S; Saito H; Sakata Y; Hyodo I
J Clin Oncol; 1999 Jan; 17(1):319-23. PubMed ID: 10458249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]